# Lingnuo (Shanghai) Pharmaceutical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lingnuo-shanghai-pharmaceutical-technology-co

- Industry: Healthcare IT
- Headquarters: Shanghai, China
- Website: www.linnopharma.com
- Latest round: Series A (Dec 2, 2024)
- Investors on record: 1

## About

Based in Shanghai, China and established in 2019, Lingnuo (Shanghai) Pharmaceutical Technology Co., Ltd. operates as a drug technology developer that focuses on antibody treatment. The company established scientific advisory committee in April 2021. Zhaozhong Han the founder of the company. The core research team of the company has more than 20 members of its total employees. In December 2024, the firm closed a series A funding.

The company provides treatment of severe chronic diseases, such as severe inflammatory disease. The company focuses on macromolecule delivery technology and selective complement inhibition. The company's product pipeline includes LIN-2001 (recombinant protein), LIN-2002 (AAV gene therapy) and LIN-2003 (recombinant protein). The company's products include best-in-class (BIC) and first-in-class (FIC), such as complement targeted antibodies, recombinant protein drugs.


The company’s revenue is generated by providing complement-targeted antibodies and recombinant protein drugs.

## Funding rounds

- Series A, Dec 2, 2024 — Tian Rui Feng Nian Private Fund

## Investors

- Tian Rui Feng Nian Private Fund (https://capitalatlas.ai/funds/tian-rui-feng-nian-private-fund) — Series A